Abstract：
:Dual antiplatelet therapy with aspirin and clopidogrel are recommended as adjuncts to fibrinolytic-treated patients with ST-elevation myocardial infarction (STEMI). However, the role of switching to ticagrelor within 24 h of fibrinolytics compared with clopidogrel continuation in this setting is uncertain. Hence, we conducted a comprehensive search of electronic databases for all randomized clinical trials (RCTs) that evaluated the safety and efficacy of ticagrelor versus clopidogrel after fibrinolytic therapy in patients with STEMI. A random-effects model was used to calculate the risk ratios (RRs) and 95% confidence intervals (CIs). A total of 5 RCTs that evaluated the efficacy of ticagrelor post-fibrinolysis were identified. We included 3 RCTs with 3999 total patients for our meta-analysis. The results showed similar short-term clinical outcomes between ticagrelor and clopidogrel with regard to rates of Bleeding Academic Research Consortium (BARC) type ≥ 2 bleeding (RR 0.94; 95% CI 0.56-1.60; P = 0.83), major adverse cardiovascular events (RR 0.87; 95% CI 0.49-1.52; P = 0.62), mortality (RR 0.92; 95% CI 0.53-1.59; P = 0.77), myocardial infarction (RR 0.76; 95% CI 0.43-1.36; P = 0.36), and stroke (RR 0.93; 95% CI 0.50-1.73; P = 0.82). Our results demonstrate that in STEMI patients treated with fibrinolytic therapy, switching to ticagrelor was associated with similar bleeding and ischemic outcomes compared with clopidogrel continuation.
journal_name
J Thromb Thrombolysisjournal_title
Journal of thrombosis and thrombolysisauthors
Kheiri B,Osman M,Abdalla A,Haykal T,Barbarawi M,Zayed Y,Hicks M,Ahmed S,Bachuwa G,Hassan M,Bhatt DLdoi
10.1007/s11239-018-1706-2subject
Has Abstractpub_date
2018-10-01 00:00:00pages
299-303issue
3eissn
0929-5305issn
1573-742Xpii
10.1007/s11239-018-1706-2journal_volume
46pub_type
杂志文章,meta分析abstract：:There were limited studies comparing the anterior (AC) and posterior (PC) circulation acute ischemic strokes (AIS). Our study aimed to evaluate distinct features of AC and PC strokes regarding clinical, vascular risk, pathogenesis and outcome factors after endovascular procedures. This multicenter prospective study re...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02054-2
更新日期：2020-05-01 00:00:00
abstract：:Anticoagulation treatment is effective in preventing both death and recurrence in patients with venous thromboembolism (VTE), but at the same time confers a substantial risk of bleeding complications. The aim of this study was to examine the rate of and predictors for bleeding complications in VTE patients on warfarin...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-015-1305-4
更新日期：2016-02-01 00:00:00
abstract：:A cardiocerebral ischemic attack (CCI) or a concurrent acute ischemic stroke (AIS) and myocardial infarction (AMI) is a severe event with no clear recommendations for ideal management because of the rarity of the scenario. The narrow time window for treatment and complexity of the treatment decision puts immense press...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-017-1484-2
更新日期：2017-07-01 00:00:00
abstract：:While antithrombotic therapy of acute myocardial infarction is clearly beneficial, substantial controversy exists regarding the optimal regimen. In particular, while aspirin alone has proven highly effective in reducing rates of reinfarction, stroke, and death following acute coronary occlusion, heparin has not clearl...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/BF01062568
更新日期：1995-01-01 00:00:00
abstract：UNLABELLED:Compression therapy is still not widely used for patients with deep vein thrombosis (DVT). This report provides information on Italian doctors' use of elastic stockings (ES) after acute DVT and identifies some predictors of prescription. MATERIAL AND METHODS:The MASTER multicenter registry collected informa...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究
doi：10.1007/s11239-009-0316-4
更新日期：2009-11-01 00:00:00
abstract：:We have applied the low molecular weight heparin dalteparin as once-daily subcutaneous injections to the treatment of deep vein thrombosis (DVT) on an outpatient basis since 1994. Until today, 377 consecutive patients with DVT below the inguinal ligament have been treated at home with dalteparin. The patients administ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1023/A:1008866025015
更新日期：1998-09-01 00:00:00
abstract：:Direct oral anticoagulant (DOAC) starter packs are designed for unique treatment dosing for acute venous thromboembolism (VTE). Inappropriate use of 30-day DOAC starter packs in patients with atrial fibrillation (AF) may increase the risk for bleeding events given higher dosing in the first 1-3 weeks of treatment. A r...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02358-3
更新日期：2021-01-03 00:00:00
abstract：:Apixaban is effective and safe for preventing stroke, and its usage has increased exponentially in recent years. However, data concerning the therapeutic range of apixaban is limited. This study determined the trough and peak levels of apixaban-specific anti-factor Xa activity (AFXaA) in acute ischemic stroke patients...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-017-1590-1
更新日期：2018-02-01 00:00:00
abstract：:Direct oral anticoagulants have been shown safe and effective in the treatment of pulmonary emboli and deep vein thrombi. Their role in the treatment of patients with hypercoagulability is uncertain. We designed a retrospective exploratory analysis of all patients with definite heparin induced thrombocytopenia (HIT) a...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-016-1420-x
更新日期：2017-01-01 00:00:00
abstract：:This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究
doi：10.1007/s11239-020-02162-z
更新日期：2020-08-01 00:00:00
abstract：:The predictive value of and the influencing factors associated with early neurological improvement (ENI) among patients with acute basilar artery occlusion (BAO) have not been well studied. The present study aimed to evaluate whether ENI predicted a better functional outcome and to identify the influencing factors of ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02153-0
更新日期：2021-01-01 00:00:00
abstract：:Tumour necrosis factor alpha (TNF-alpha) and interlekin-6 (IL-6) are key inflammatory cytokines in the pathogenesis of rheumatoid arthritis (RA), a disease also associated with endothelial perturbation and increased serum levels of adhesion molecules. As relationships between these processes and molecules are unclear,...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1007/s11239-009-0370-y
更新日期：2010-05-01 00:00:00
abstract：:No study investigated the possible detrimental effect of stress hyperglycemia on patients affected acute ischemic stroke (AIS) undergoing intravenous thrombolysis (IVT). A new index, the glucose-to-glycated hemoglobin ratio (GAR), has been developed for assessing stress hyperglycemia. We retrospectively analyzed data ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02252-y
更新日期：2020-08-24 00:00:00
abstract：:The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known. This was a randomised, open-label, crossover PD/PK study of 40 Hispanic...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11239-014-1135-9
更新日期：2015-01-01 00:00:00
abstract：:Several newer anticoagulants are under clinical development. Recently two of them, Dabigatran etexilate/Pradaxa. and Rivaroxaban/Xarelto obtained marketing authorization in Europe and Canada for the prevention of thromboembolic events following major orthopedic surgery such as total hip and knee replacement. The resul...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-009-0392-5
更新日期：2010-01-01 00:00:00
abstract：:Sickle cell disease (SCD) is characterised by abnormal coagulopathy and angiogenesis although their relationships in two common genotypes, homozygous (HbSS) SCD and sickle-haemoglobin C disease (HbSC), are unexplored. We measured markers of platelet activation (soluble P-selectin [sP-selectin]), fibrinolysis (D-dimer)...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-007-0177-7
更新日期：2008-04-01 00:00:00
abstract：AIMS:Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-006-9001-z
更新日期：2007-02-01 00:00:00
abstract：:Kuperman et al. found that patients with anemia had a higher risk of major bleeding (RR 2.84; 95% CI 2.52-3.39) in RIETE database. Anemia appeared to be an independent predictive factor for major bleeding [hazard ratio (HR) 1.95; 95% CI 1.72-2.20] in this registry. Unfortunately, selection bias due to enrolled patient...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 信件,多中心研究
doi：10.1007/s11239-018-1668-4
更新日期：2018-07-01 00:00:00
abstract：:Erythropoietin (EPO) was hypothesized to mitigate reperfusion injury, in part via mobilization of endothelial progenitor cells (EPCs). The REVEAL trial found no reduction in infarct size with a single dose of EPO (60,000 U) in patients with ST-segment elevation myocardial infarction. In a substudy, we aimed to determi...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1007/s11239-013-0944-6
更新日期：2013-11-01 00:00:00
abstract：:Hyperhomocysteinemia (HHcy) affects haemostasis and shifts its balance in favour of thrombosis. In vitro and in vivo studies suggested that HHcy may impair fibrinolysis either by influencing the plasma levels of fibrinolytic factors or by altering the fibrinogen structure. We investigated the influence of mild HHcy le...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-013-0981-1
更新日期：2014-07-01 00:00:00
abstract：:Stroke and venous thromboembolism (VTE) are serious and preventable thrombotic events in patients with atrial fibrillation (AF) and who undergo surgery or hospitalization, respectively. Nevertheless, thromboprophylaxis remains greatly underused. The National Quality Forum, the Agency for Healthcare Research and Qualit...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-013-0874-3
更新日期：2014-01-01 00:00:00
abstract：:Intravenous (IV) thrombolysis is the treatment in ischemic stroke, but only the minority of patients receive this medication. The primary objective of this study was to explore the reasons associated with the decision not to offer IV thrombolysis to stroke patients admitted to the Stroke Unit (SU). We conducted a retr...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-016-1406-8
更新日期：2016-11-01 00:00:00
abstract：:Ischemic stroke and major bleeding, mostly due to intracranial hemorrhage (ICH), cause about the same rates of death in pivotal randomized trials of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in atrial fibrillation (AF). We analyzed our AF inpatient database to determine whether any ICH-r...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-018-1767-2
更新日期：2019-02-01 00:00:00
abstract：:Fondaparinux (FPX), a selective inhibitor of factor Xa, is widely used for the prophylaxis of venous thromboembolism (VTE) after total joint arthroplasty. However, the association between plasma FPX concentration and adverse events and the occurrence of VTE has not been clarified thus far. We aimed to prospectively ev...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-012-0773-z
更新日期：2012-11-01 00:00:00
abstract：:High central aortic pulse pressure (CPP) and thrombin-induced platelet-fibrin clot strength (TIP-FCS) have been associated with ischemic outcomes in patients with coronary artery disease in separate studies. But, the ischemic risk associated with these factors has never been analyzed in a single study and their interr...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-017-1524-y
更新日期：2017-08-01 00:00:00
abstract：:Data comparing the patient characteristics, management and outcomes for dabigatran versus warfarin major bleeding in the practice setting are limited. We performed a retrospective single health system study of atrial fibrillation patients with dabigatran or warfarin major bleeding from October 2010 through September 2...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-015-1213-7
更新日期：2015-10-01 00:00:00
abstract：:The risk benefit decision in providing anticoagulation for patients with brain metastases is amongst the most difficult decisions faced by clinicians. The purpose of our study was to evaluate both the risk of intracerebral hemorrhage (ICH) associated with anticoagulation therapy and the effect of anticoagulation on su...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,meta分析,评审
doi：10.1007/s11239-017-1536-7
更新日期：2017-10-01 00:00:00
abstract：:Poloxamer 188 is a surfactant with hemorheological, antithrombotic, and neutrophil-inhibitory properties. This agent has been demonstrated to reduce infarct size and to improve left ventricular function in animal models of myocardial infarction and reperfusion, and recently in a randomized trial of patients receiving ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1023/A:1008848026759
更新日期：1998-07-01 00:00:00
abstract：:Inherited afibrinogenemia and hypofibrinogenemia are rare bleeding disorders characterized by markedly reduced levels of fibrinogen in blood. Thrombotic complications in these disorders have been rarely described. We performed a multicenter retrospective study and reviewed the occurrence of thrombotic complications am...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,多中心研究
doi：10.1007/s11239-015-1325-0
更新日期：2016-08-01 00:00:00
abstract：:Acute myocardial infarction is initiated by plaque disruption of a fatty plaque with a thin fibrous cap which has been infiltrated by macrophages. The macrophages are attracted and stimulated by oxidized lipids to secrete metalloproteinases which dissolve collagen and arterial wall matrix and to synthesize tissue fact...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/BF01060732
更新日期：1995-01-01 00:00:00
